View printer-friendly version

Emergent BioSolutions to Lead a United States Delegation to the United States – India Business Council (a Subsidiary of the US Chamber of Commerce) Health Summit in India

Summit Will Focus on Improving the Quality of Healthcare in India

ROCKVILLE, Md.–(BUSINESS WIRE)–Nov. 12, 2007–Emergent BioSolutions, Inc. (NYSE:EBS) announced today that the company is leading a delegation to the United States – India Business Council’s (USIBC) Healthy India Summit. Dr. Thomas Zink, the Chief Medical Officer and Senior Vice President for Clinical, Medical, and Regulatory Affairs of Emergent BioSolutions, and Dr. Lallan Giri, Vice-President, Science and Business Relations of Emergent BioSolutions, are leading the delegation on behalf of the company. The summit is taking place in New Delhi, India, today, November 12th through November 15th.

The Coalition for Healthy India is committed to improving healthcare outcomes for Indian patients by enabling affordable access to the latest and best treatments and cures. The theme of the conference is “Raising the Standard of Care for Indian Patients” and will focus on a dialogue among leaders and experts in the medical, scientific, and business industries aimed at promoting awareness and developing solutions to address the critical need for healthcare improvements in India.

“Emergent BioSolutions’ mission is to protect life and our company is honored to lead this important delegation to the 4th India Health Summit on Healthcare Engagement Strategies and Partnerships which is focused on not only protecting but improving life,” stated Dr. Thomas Zink, Chief Medical Officer and Senior Vice President for Clinical, Medical and Regulatory Affairs, Emergent BioSolutions. “We are grateful to the United States – India Business Council for their partnership and look forward to joining experts and industry peers from around the world, who share our commitment to improving the quality of life in India.”

Emergent BioSolutions’ product portfolio includes a drinkable Typhoid vaccine candidate, a Hepatitis B therapeutic vaccine candidate, Group B streptococcus vaccine candidate, a Chlamydia vaccine candidate, among others. The company announced last month that preliminary results from a Phase II clinical study demonstrated that its single-dose, drinkable typhoid vaccine candidate achieved the study endpoints for safety and immunogenicity. Typhoid is particularly prevalent in India.

The USIBC, a subsidiary of the United States Chamber of Commerce, is the premier business advocacy organization representing America’s top companies investing in India, joined by global Indian companies promoting economic reforms with an aim to deepen trade and strengthen commercial ties. The USIBC was formed in 1975 at the request of both the governments of the United States and India, to enhance investment flows between the two countries, and serve as a direct link between business and government leaders. The Council’s primary mission is to increase trade and investment between India and the United States.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission–to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including our expected revenue growth and net earnings for 2007, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including our ability to obtain new BioThrax(R) sales contracts with the U.S. government; our plans for future sales of BioThrax; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.